A detailed history of Suvretta Capital Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Suvretta Capital Management, LLC holds 689,950 shares of ACLX stock, worth $61.1 Million. This represents 2.27% of its overall portfolio holdings.

Number of Shares
689,950
Previous 1,516,254 54.5%
Holding current value
$61.1 Million
Previous $83.7 Million 31.15%
% of portfolio
2.27%
Previous 3.5%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$50.91 - $86.61 $42.1 Million - $71.6 Million
-826,304 Reduced 54.5%
689,950 $57.6 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $2.29 Million - $3.09 Million
-46,100 Reduced 2.95%
1,516,254 $83.7 Million
Q1 2024

May 15, 2024

SELL
$51.85 - $73.49 $45.3 Million - $64.2 Million
-873,620 Reduced 35.86%
1,562,354 $109 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $13.8 Million - $25.2 Million
-433,993 Reduced 15.12%
2,435,974 $135 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $686,918 - $815,320
21,800 Added 0.77%
2,869,967 $103 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $12.4 Million - $21.1 Million
449,846 Added 18.76%
2,848,167 $90.1 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $1.29 Million - $1.63 Million
47,988 Added 2.04%
2,398,321 $73.9 Million
Q4 2022

Feb 14, 2023

BUY
$17.18 - $33.0 $1.73 Million - $3.33 Million
100,800 Added 4.48%
2,350,333 $72.8 Million
Q3 2022

Nov 14, 2022

SELL
$16.67 - $22.04 $3.68 Million - $4.87 Million
-221,026 Reduced 8.95%
2,249,533 $42.2 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $6.76 Million - $22.9 Million
937,500 Added 61.15%
2,470,559 $44.7 Million
Q1 2022

May 16, 2022

BUY
$12.97 - $19.14 $19.9 Million - $29.3 Million
1,533,059 New
1,533,059 $21.5 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.88B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Suvretta Capital Management, LLC Portfolio

Follow Suvretta Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Suvretta Capital Management, LLC with notifications on news.